Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report
BMC Psychiatry – January 02, 2024
Source: CrossRef
Summary
Ketamine, used therapeutically for depression, can cause ulcerative cystitis (KIC), a condition previously linked only to recreational use. A 28-year-old woman developed KIC symptoms after starting ketamine treatment, confirmed by urine analysis. This marks the first documented instance of KIC in a patient receiving therapeutic-dose ketamine, a complication seen in over 25% of recreational users. This discovery highlights a crucial consideration for patients and clinicians using this emerging antidepressant.
Abstract
Abstract Background Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although Ketamine-induced cystitis (KIC) is a recognised complication in recreational use of ketamine, its occurrence in therapeutic use of ketamine in depression has so far not been reported. The exact pathogenesis of KIC is currently unknown, making treatment and prevention advice much more difficult. Early diagnosis of KIC and immediate cessation of ketamine has been shown to improve adverse urinary tract symptoms and prevent further damage. Case presentation We present a case of a 28-year-old female who was started on ketamine treatment for depression, and who then developed symptoms of KIC, which was confirmed by urine microscopy, culture and analysis. Conclusions To our knowledge, this is the first reported case of KIC in a patient receiving treatment-dose ketamine as part of their antidepressant therapy.